JUNO IPO's and hits a 3B market cap and they're just getting started in human trials based on this CEO comment: "We have 10 clinical candidates moving into the clinic next year," says CEO Hans Bishop..."
Seems like same old.. same old... options expire tomorrow and 10 is the battle line.
Any guess what the capital gains payout might be at EOY? I think last year was about .36 per share... so I'm hoping to effectively three times the normal payout for December.
I'm looking to the fund for monthly income and want to reinvest in the fund, but on a bi-annual basis given the NAV should drop at least for two years as interest rates rise. The effective maturity after hedging is a bit over 4 years for the fund per the Pimco web site. I'm a newbie to bonds so I'm placing a lot of faith in Pimco management to make good choices when purchasing bonds, so reduce the chance of defaults. Pimco web site states 2.6% of fund is E&P.
Avanir acquired at 3.5B... amazing given the following. Makes one only wonder what MACK could be acquired for in three to five years when the pipeline is matures.
Avanir currently sells just one product, Neudexta, a co-formulation of two generic drugs used to treat uncontrollable laughing and crying associated with pseudobulbar affect, a secondary ailment associated with neurological disease or brain injury. This has brought 12-month sales to $104 million, though Avanir has yet to make any money.
I'm wondering if shorts are easing off because there seems to be no interest in buying cheap Dec calls at the 11 or 12. Normally shorts will scoop up calls sold by shareholders to hedge their short positions. It's as if they are not rolling them forward.
I've noticed MACK's price moves up to or slightly above the next options strike usually within ten days of expiration, then always manages to close below the strike price on the expiration date. For Friday's expiration, IMHO MACK's price will close below nine.
So far the sell-off not too bad in after hours, but where do you think the bottom is? I'm thinking shorts pile on Monday morning, so it might be a buying opportunity as the stock price resets perhaps to 12 split adjusted.
Been there before with AEZS and perifosine... IMHO sell it. Unfortunately, that first chance to sell is always the dead cat bounce just after the open when the day traders cover their short position. Normally these things spiral down, find a bottom, then may recover a small amount.
Buy MACK on dips, hold for five years, and triple your money with a lot less risk.
Yes, I've seen this in Atrium and sold too soon. The stock traded below value for so long I got frustrated and sold... only to see it bought out at a 100% premium.
IMHO we'll get a window on Baxter's interest if they partner with MM-121. It would then seem possible they wait until after FDA approval, then perhaps make an offer to buy out the company. Remember Actavis is also in the picture.
If yet another pharma picks up MM-121, it complicates a takeover because there would then be three companies in the mix, including Actavis and Baxter. I'm still waiting to hear from Actavis next year.
Check out nat gas export factilities. This is something Obama favors as well as the GOP. With low gasoline prices, the window opens to change the laws soon, for exporting both nat gas and oil. IMHO given the cost of exporting nat gas, it won't have too much effect on prices here in the US.
Bing it: U.S. Natural Gas Exports Will Fire Up in 2015
Bing it: Solar latecomer France builds Europe's largest plant
CSIQ is one of the three suppliers of solar panels.
Umm... they do determine export laws for nat gas and oil. The also determine the extension of Federal tax credits for residential renewable energy in the US, due to expire end of 2016. (Residential Renewable Energy Tax Credit)
Election results. Republicans have never been pro-green and do not believe carbon emissions are causing climate change.
Note that all the fossil fuel stocks and MLPs are up. IMHO we'll see acceleration of oil and nat gas exports. This is something both Obama and the Republicans favor. While gas prices are low, the door opens to get this legislation passed without infuriating gas-price sensitive voters.
Note many shareholders that bought around the time the MM-398 study was extended are now reaching their one year anniversary. Profits would now be taxed as a long term capital gain.
The strangle looks somewhat bullish, because the stock must reach 7.75 to break even, given the puts cost 75 cents. That's a pretty large jump in price even on good results in just a few days (10/17 - 10/22). If results are bad, he breaks even if the stock reaches 3.35 given each call cost 30 cents and he bought three calls for each put. I'm just wondering if the results might be neutral given NBS seems to be waiting until 10/17 to release any news.